Background: Combined therapy involving cytoreductive surgery (CRS) and perioperative intraperitoneal chemotherapy has been shown to improve survival outcomes for patients with diffuse malignant peritoneal mesothelioma (DMPM). The present study aims to investigate gender as a potential prognostic factor on overall survival.
introduction
Diffuse malignant peritoneal mesothelioma (DMPM) is a rare but aggressive disease with a poor response to systemic chemotherapy [1] . Although the pathogenesis of DMPM is likely multifactorial, there is strong evidence suggesting a casual association with exposure to asbestos [2, 3] . Due to the latency time between asbestos exposure and disease progression, the incidence of DMPM is expected to peak in many industrialized nations over the coming decade [4, 5] . Since the introduction of cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC), there has been growing evidence that this combined treatment modality can offer improved long-term survival for selected patients [6, 7] .
Recently, there has been a joint effort to create a TNM (tumor-node-metastasis) staging system for patients who undergo CRS and perioperative intraperitoneal chemotherapy, with the intention of improving prognostication [8] .
The incidence of DMPM is significantly higher in men, possibly related to their increased occupational exposure to asbestos [4, 9] . Female gender has been previously reported as a favorable prognostic factor [10] [11] [12] . However, this finding has been inconsistent, possibly due to the limited number of patients recruited for each individual study [11, [13] [14] [15] . The primary objective of the present study was to assess the prognostic significance of gender in patients with DMPM, using a cohort of patients who underwent CRS and perioperative intraperitoneal chemotherapy from a large multi-institutional registry.
patients and methods
Patients included in the present study were selected from a multiinstitutional registry that included 405 consecutive patients with histologically proven DMPM who were considered preoperatively to be candidates for CRS and perioperative intraperitoneal chemotherapy between October 1989 and February 2009. Each of the eight participating institutions that contributed to the registry obtained ethics approval through their institutional review board or through the chairperson of their ethics committee. After excluding 110 patients with unknown peritoneal cancer index (PCI) and 4 patients who were lost to follow-up, a total of 294 patients with complete clinicopathologic and follow-up data were included for statistical analysis.
All patients included in the present study underwent CRS and HIPEC, with the intention of achieving maximal cytoreduction as described by Sugarbaker [16] . Briefly, six different peritonectomy procedures were carried out in various combinations, including: (i) greater omentectomy with splenectomy, (ii) left upper quadrant peritonectomy, (iii) right upper quadrant peritonectomy, (iv) lesser omentectomy with cholecystectomy, (v) pelvic peritonectomy with resection of the rectosigmoid colon, and (vi) antrectomy. The most commonly used chemotherapy regimen for HIPEC was cisplatin and doxorubicin, with some variations of duration (30-120 min), intraperitoneal temperature (40-43°C), and exposure technique (open or closed) between institutions.
standardized data form
A blinded standard data form was created to retrieve relevant clinicopathologic and treatment-related information, including age, sex, date of surgery, extent of prior surgical intervention, performance status, histopathologic subtype, presence of lymph node metastasis, presence of extra-abdominal metastasis, PCI, completeness of cytoreduction, receipt of HIPEC, receipt of early-postoperative intraperitoneal chemotherapy (EPIC), duration of surgery, perioperative blood transfusion £5 or >5 U, presence versus absence of cardiac, respiratory, gastrointestinal, renal, and hematologic complications, presence versus absence of grades 3-4 toxicity according to the National Cancer Institute Common Toxicity Criteria, duration of hospital stay, and receipt of long-term pemetrexed and cisplatin systemic chemotherapy.
quantitative assessment
The volume and extent of the tumor deposits were recorded prospectively by using the PCI. This assessment combines lesion size (0-3) with tumor distribution (abdominal-pelvic regions, 0-12) to quantify the extent of disease as a numerical score (0-39). Completeness of resection was measured prospectively in all patients by the completeness of cytoreduction score (CCR score). CCR-0 indicated that no residual disease was visible after cytoreduction. CCR-1 indicated that tumor nodules were present but <2.5 mm in diameter. CCR-2 indicated tumor nodules were between 2.5 mm and 2.5 cm in diameter, and CCR-3 indicated tumor nodules were >2.5 cm in diameter or a confluence of unresectable tumor nodules was present at any site [17] .
statistical analysis
For univariate analysis, the chi-square (or Fisher's exact) test was used for categorical variables. Overall survival analysis was carried out using the Kaplan-Meier method and compared using the log-rank test. Survival was calculated from the date of the surgery to the last date of follow-up or death. A significant difference was predetermined to be P < 0.05. For multivariate analysis, a Cox regression model with a forward stepwise selection of covariates and with entering and removing limits of P < 0.10 and P > 0.05 was used. These analyses were carried out using SPSS for Windows (Version 18.5; SPSS GmbH, Munich, Germany). Perioperative mortality was defined as any death that occurred within the first 30 days of surgery or during the same hospital admission. Perioperative mortality was not excluded from the overall survival analysis.
results clinicopathologic data
Between October 1989 and February 2009, a total of 294 consecutive patients with DMPM who had complete clinicopathologic and follow-up data were extracted from our multi-institutional registry. The median follow-up was 25 months (0-235 months). The mean age at the time of surgery was 50 years [standard deviation (SD), 14 years]. There were 135 (46%) female patients. Performance status according to the World Health Organization criteria was £2 in 171 (58%) patients. Two hundred fifty-nine patients (88%) had epithelial tumors, and 27 patients (9%) had biphasic or sarcomatoid tumors. Twenty-two patients (7%) had lymph node metastases and 12 patients (4%) had extra-abdominal metastases. The mean PCI was 20 (SD, 10). When clinicopathologic data were compared between male and female patients, PCI was found to be significantly lower in female patients (P < 0.001). In addition, there was a significantly lower stage of disease in female patients (P = 0.001) and they were more likely to be treated with HIPEC compared with male patients (P = 0.022).
treatment-related data
At the completion of CRS, 74 patients (25%) had CCR-0, 65 patients (22%) had CCR-1, 38 patients (13%) had CCR-2, and 35 patients (12%) had CCR-3. According to the newly proposed TNM staging system, there were 52 patients (18%) who had stage I disease, 166 (56%) with stage II disease, and 76 (26%) with stage III disease. The difference between male and female patients was significant (P = 0.001). The mean operating time was 8.7 h (SD, 2.7 h). Thirty patients (10%) had a packed-cell transfusion of >5 U. Two hundred sixty-eight patients received HIPEC and 207 patients (70%) received EPIC. Postoperatively, 7 patients (2%) experienced cardiac complications, 33 patients (11%) experienced respiratory complications, 51 patients (17%) experienced bowelrelated complications, 26 patients (9%) experienced renal complications, and 16 patients (5%) developed hematologic toxicity. Overall, 97 patients (33%) had perioperative complications. Seven patients (2%) died during the perioperative period. The mean length of hospital stay was 23 days (SD, 14 days). When treatment-related data were compared between genders, female patients were found to have significantly lower staged disease (P = 0.001), and more female patients were able to undergo HIPEC therapy (P = 0.022). A summary of clinicopathologic and treatment-related data is presented in Table 1 .
survival outcome
The median overall survival of the 294 patients included in the present study was 67 months (range 0-235 months), with 1-, 3-, and 5-year survival rates of 83%, 62%, and 52%, respectively, as shown in Figure 1 . Female patients were found to have a significantly improved survival when compared with male patients (P < 0.001). The overall 1-, 3-, and 5-year survival rates for female patients were 89%, 76%, and 68%, respectively, compared with 77%, 50%, and 39% in male patients, as shown in Figure 2 . Staging according to the recently proposed TNM system remained to be a significant prognostic factor when applied separately to female patients (P = 0.003) and male patients (P < 0.001), as demonstrated in Figure 3 . When patients with DMPM were stratified according to gender and staging, it was found that female patients with stage I disease had a 3-year survival of 97.1%. When patients were categorized according to age and gender, female patients aged £55 years had significantly better overall survival compared with female patients >55 years (P = 0.019). This finding was not found in male patients when they were divided according to age < or >55 years (P = 0.287).
discussion
The present study was the largest to date to evaluate the survival differences between genders for patients with DMPM who original articles Annals of Oncology underwent CRS and HIPEC. Data were collected from a multiinstitutional registry using a standardized form that included a number of clinicopathologic and treatment-related factors. Results of our study suggest that there is a significant difference in long-term survival between female and male patients, and that age beyond the postmenopausal period was a significant prognostic factor for female patients but not for males.
In the past, no uniformly accepted and reliable TNM staging system for peritoneal mesothelioma existed. Our group has proposed a novel TNM in which the T category is determined by the PCI, which was categorized into four subgroups with T1 (PCI 1-10), T2 (PCI [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] , T3 (PCI 21-30), and T4 (PCI 31-39). This classification of the PCI was associated with a significant difference in survival. When combined with the N factor (lymph node status) and the M factor (extraabdominal disease), a stage I group, stage II group, and stage III group was identified [8] . Not only in peritoneal mesothelioma but also in colorectal cancer, the PCI has been shown to be a dominant predictor of outcome when patients are treated with CRS and HIPEC. Elias et al. [18] demonstrated this finding in his multivariate analysis of prognostic factors for overall survival in 523 patients with colorectal carcinomatosis (P < 0.001, HR 1.052). Another important prognostic indicator of peritoneal surface malignancies is the CCR score. However, CCR score cannot be used in a staging system because it is determined after the surgery is complete, in contrast to PCI, which can be determined at the time of abdominal exploration before definitive treatment [17] . Recent studies have also found that important information regarding the PCI can be obtained from preoperative computed tomography scans in patients with peritoneal mesothelioma [18] .
The importance of gender as a potential prognostic factor in patients with malignant mesothelioma has been evaluated in previous studies [19] [20] [21] . An institutional report from the Washington Institute involving 34 men and 28 women found the median overall survival to be significantly longer in female patients. In addition, women were found to present with less extensive peritoneal involvement at the time of CRS and were more likely to have tumors that had favorable histopathological patterns [20] . More recently, a study on malignant pleural mesothelioma involving 702 patients who underwent extrapleural pneumonectomy found that women with epithelial disease had significantly longer survival on multivariate analysis. Authors of this study suggested that female patients were much less likely to present with non-epithelial disease. In addition, they reported an inherent survival advantage in female patients with epithelial disease that was not present in female patients with non-epithelial disease [21] . The rationale for improved survival outcomes in female patients diagnosed with DMPM has not been clearly elucidated. Previous studies have hypothesized that differences in the natural history of DMPM between genders may be related to differences in occupational asbestos exposure [3] . However, the pathogenesis of DMPM in female patients is not limited to contact with asbestos, and the linkage between DMPM with asbestos is weaker than in malignant pleural mesothelioma [2, 22] . Pinton et al. [19] explored the prognostic significance of estrogen receptor (ER) expression in 78 patients with malignant pleural mesothelioma and found the expression of estrogen b (but not estrogen a) receptors to be an independent predictor of improved survival. Furthermore, this group tested the potential tumor suppressing properties of ERb by conducting in vitro studies, which reported comparable findings. An overexpression of ERb resulted in malignant mesothelioma cell growth arrest, while 17h-estradiol inhibited malignant mesothelioma cell proliferation via ERb. Although the precise mechanism of these findings remains uncertain, the authors concluded that there was clearly a suppressive role of ERb in malignant mesothelioma. Another study that examined the differential expression of Ki-67 and sex steroid hormone receptors between genders in 20 patients with DMPM reported a higher expression of Ki-67 in males and a higher expression of estrogen and progesterone receptors in females [23] . Similar to the results of the current study, female patients were found to have a significantly lower PCI at the time of surgery and achieve a longer overall survival. Findings from this study provided further speculation that the expression of sex steroid hormone receptors may confer a protective effect, especially in females. One may hypothesize that the gender differences shown in this manuscript are related to differences in the stage of disease at the time of definitive treatment. However, Figure 3 clearly shows a difference in survival by gender at all stages of the disease process. It suggests that male patients with peritoneal mesothelioma have a fundamentally different disease process or that the host-tumor relationship is fundamentally different between genders. One can draw a conclusion that the tumor biology of peritoneal mesothelioma in male and female patients is distinctly separate.
Female patients from the present study over the age of 55, who were likely to be postmenopausal, were found to have a significantly worse survival outcome than younger women. When the same age categorization was applied to male patients, no significant difference in survival was found. 
